Biotech

All Articles

Genentech to shut cancer immunology analysis team

.Genentech will close its own cancer cells immunology research study team, as well as unit head and ...

Kezar loses strong lump yet to verify its worth in phase 1 trial

.Kezar Life Sciences is dropping its unpromising phase 1 strong cyst medication as the biotech goes ...

Acelyrin drops izokibep, lets go 3rd of workers

.Despite izokibep preserving its own newly found winning touch in the center, Acelyrin is actually n...

Rivus' phase 2 obesity-related cardiac arrest trial hits endpoint

.Rivus Pharmaceuticals has actually plumped up the customers of its own fat-busting, muscle-sparing ...

Ovid stops preclinical job, IV system after soticlestat fall short

.Ovid Therapeutics presently showed last month that it was trimming its own headcount as the firm na...

Eli Lilly opens $700M nucleic acid R&ampD center in Boston Seaport

.Eli Lilly has opened up a $700 million R&ampD center in the Boston Seaport, improving its RNA and a...

Boundless Bio makes 'moderate' layoffs five months after $100M IPO

.Merely 5 months after getting a $100 million IPO, Limitless Biography is actually currently giving ...

Halda's $126M will definitely accelerate 'secure and also eliminate' tumor drugs

.The first stages of oncology R&ampD aren't except fascinating brand new modalities, and Halda Thera...

Lykos 'remorses' not revealing research offenses with publisher

.Psychopharmacology has drawn 3 write-ups regarding midstage professional test data determining Lyko...

Analysts go into Avidity's DMD gain, uncovering subtleties in data

.Avidity Biosciences pleased capitalists with period 1/2 data in Duchenne muscle dystrophy (DMD) Fri...